STOCK TITAN

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Lexicon Pharmaceuticals (LXRX) announced the publication of research findings on sotagliflozin in the Journal of American Society of Nephrology. The study analyzed the drug's efficacy and safety when combined with insulin in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD). Key findings show that sotagliflozin achieved similar HbA1c reductions in both CKD and non-CKD patients, with significant placebo-adjusted reductions of -0.4% for 200mg and -0.3% to -0.4% for 400mg doses. The drug demonstrated a lower to neutral risk of severe hypoglycemia and did not significantly increase diabetic ketoacidosis risk. The FDA has set a PDUFA date of December 20, 2024, for Zynquista (sotagliflozin).

Lexicon Pharmaceuticals (LXRX) ha annunciato la pubblicazione dei risultati di una ricerca su sotagliflozin nel Journal of American Society of Nephrology. Lo studio ha analizzato l'efficacia e la sicurezza del farmaco quando combinato con insulina in pazienti con diabete di tipo 1 (T1D) e malattia renale cronica (CKD). I risultati chiave mostrano che sotagliflozin ha raggiunto riduzioni simili dell'HbA1c sia nei pazienti con CKD che in quelli senza, con significative riduzioni aggiustate per placebo di -0,4% per dosi da 200mg e -0,3% a -0,4% per dosi da 400mg. Il farmaco ha dimostrato un rischio da basso a neutro di grave ipoglicemia e non ha aumentato significativamente il rischio di chetoacidosi diabetica. La FDA ha fissato una data PDUFA per il 20 dicembre 2024, per Zynquista (sotagliflozin).

Lexicon Pharmaceuticals (LXRX) anunció la publicación de los hallazgos de una investigación sobre sotagliflozina en el Journal of American Society of Nephrology. El estudio analizó la eficacia y seguridad del fármaco cuando se combina con insulina en pacientes con diabetes tipo 1 (T1D) y enfermedad renal crónica (CKD). Los hallazgos clave muestran que sotagliflozina logró reducciones similares en HbA1c tanto en pacientes con CKD como en aquellos sin CKD, con reducciones ajustadas por placebo significativas de -0,4% para dosis de 200mg y de -0,3% a -0,4% para dosis de 400mg. El fármaco demostró un riesgo de hipoglucemia severa bajo o neutro y no aumentó significativamente el riesgo de cetoacidosis diabética. La FDA ha establecido una fecha PDUFA del 20 de diciembre de 2024, para Zynquista (sotagliflozina).

Lexicon Pharmaceuticals (LXRX)는 미국신장학회 저널(Journal of American Society of Nephrology)에 sotagliflozin에 관한 연구 결과를 발표했습니다. 이 연구는 제1형 당뇨병(T1D) 및 만성 신장 질환(CKD) 환자에서 인슐린과 병행했을 때 약물의 효능과 안전성을 분석했습니다. 주요 결과는 sotagliflozin이 CKD 환자와 비 CKD 환자 모두에서 유사한 HbA1c 감소를 나타냈으며, 200mg의 경우 -0.4%, 400mg의 경우 -0.3%에서 -0.4%의 유의미한 위약 조정 감소를 보였다는 것입니다. 이 약물은 중증 저혈당의 위험이 낮거나 중립적였으며, 당뇨병성 케톤산증의 위험을 유의미하게 증가시키지 않았습니다. FDA는 Zynquista (sotagliflozin)에 대해 2024년 12월 20일로 PDUFA 날짜를 설정했습니다.

Lexicon Pharmaceuticals (LXRX) a annoncé la publication de résultats de recherche sur le sotagliflozine dans le Journal of American Society of Nephrology. L'étude a analysé l'efficacité et la sécurité du médicament lorsqu'il est associé à de l'insuline chez des patients atteints de diabète de type 1 (T1D) et de maladie rénale chronique (CKD). Les résultats clés montrent que le sotagliflozine a permis des réductions similaires de l'HbA1c tant chez les patients atteints de CKD que chez ceux sans CKD, avec des réductions ajustées par placebo significatives de -0,4 % pour des doses de 200mg et de -0,3 % à -0,4 % pour des doses de 400mg. Le médicament a démontré un risque faible à neutre de sévérité hypoglycémique et n'a pas significativement augmenté le risque de acidocétose diabétique. La FDA a fixé une date PDUFA au 20 décembre 2024 pour Zynquista (sotagliflozine).

Lexicon Pharmaceuticals (LXRX) gab die Veröffentlichung von Forschungsergebnissen zu Sotagliflozin im Journal of American Society of Nephrology bekannt. Die Studie analysierte die Wirksamkeit und Sicherheit des Medikaments in Kombination mit Insulin bei Patienten mit Typ-1-Diabetes (T1D) und chronischer Nierenerkrankung (CKD). Die wichtigsten Ergebnisse zeigen, dass Sotagliflozin sowohl bei CKD- als auch bei nicht-CKD-Patienten ähnliche HbA1c-Reduktionen erzielte, mit signifikanten placebo-adjustierten Reduktionen von -0,4% für 200mg und -0,3% bis -0,4% für 400mg-Dosen. Das Medikament zeigte ein niedriges bis neutrales Risiko für schwere Hypoglykämie und erhöhte das Risiko für diabetische Ketoazidose nicht signifikant. Die FDA hat für Zynquista (Sotagliflozin) ein PDUFA-Datum auf den 20. Dezember 2024 festgelegt.

Positive
  • Significant HbA1c reductions achieved in both CKD and non-CKD patients
  • Lower incidence of severe hypoglycemia in CKD patients (4-7% vs 17% placebo)
  • FDA PDUFA date set for December 20, 2024, indicating potential near-term approval
Negative
  • Small increase in DKA events in CKD patients (3-5% vs 1% placebo)
  • No significant effect on systolic blood pressure in CKD subgroup in inTandem1 and 2 trials

Insights

The publication of sotagliflozin's clinical trial data in JASN represents a significant milestone for Lexicon Pharmaceuticals. The data shows comparable HbA1c reduction in T1D patients with and without CKD, with placebo-adjusted reductions of -0.4% for 200mg and -0.3% for 400mg doses in the CKD subgroup. Notably, the drug demonstrated a favorable safety profile with lower rates of severe hypoglycemia in CKD patients (4-7% vs 17% for placebo) and manageable DKA risk.

With the PDUFA date approaching on December 20, 2024, these peer-reviewed results strengthen sotagliflozin's position for FDA approval. The data is particularly significant as it addresses an unmet medical need in T1D patients with CKD, a population that hasn't seen new treatment options in decades. The positive efficacy and safety profile could support broad adoption if approved, potentially expanding Lexicon's market opportunity in this specialized segment.

People with T1D and CKD treated with sotagliflozin and insulin had similar lowering effects on glycated hemoglobin (HbA1c), the primary endpoint, as people with T1D who do not have CKD

Sotagliflozin was associated with a lower to neutral risk of severe hypoglycemia and did not significantly increase the risk of diabetic ketoacidosis (DKA) among a small number of DKA events

THE WOODLANDS, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the peer-reviewed Journal of American Society of Nephrology (JASN) has published a research paper analyzing the efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, when added to insulin in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD).

The findings from the study, “Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD,” concluded that people with T1D and CKD treated with sotagliflozin and insulin had similar lowering effects on glycated hemoglobin (HbA1c), the primary endpoint of the underlying clinical trials, as T1D patients who do not have CKD. Further, the findings show that sotagliflozin was associated with a lower to neutral risk of severe hypoglycemia and did not significantly increase the risk of diabetic ketoacidosis (DKA) among a small number of DKA events.

Researchers used data from the 52-week pooled inTandem1 and 2 trials and the 24-week inTandem3 trial to assess the effects of sotagliflozin (200mg [inTandem 1&2 only] or 400mg daily) versus placebo on HbA1c (primary endpoint), body weight, systolic blood pressure (BP), insulin dose, and safety endpoints including adjudicated severe hypoglycemia and DKA, in each case stratified by CKD.

Of the 1,575 patients in the inTandem1 and 2 trials, 237 patients were identified who had CKD. Of the 1,402 patients in the inTandem3 trial, 228 patients were identified who had CKD.

At week 24, significant, placebo-adjusted reductions in HbA1c were observed in inTandem1 and 2: Non-CKD subgroup (sotagliflozin 200mg: -0.4%, 95% CI -0.4 to -0.3; 400mg: -0.4%, 95% CI -0.5 to -0.3) and CKD subgroup (sotagliflozin 200mg: -0.4%, 95% CI -0.6 to -0.1; 400mg: -0.3%, 95% CI -0.5 to -0.1). For systolic BP, there was a significant placebo-adjusted reduction at week 24 with sotagliflozin in the non-CKD subgroup but no effect in the CKD subgroup in inTandem1 and 2. At week 52, the incidence of severe hypoglycemia was lower with sotagliflozin (7% on 200 mg and 4% on 400 mg) compared to placebo (17%) in the CKD subgroup of inTandem1 and 2, whereas the incidence of severe hypoglycemia was 5-6% across both sotagliflozin and placebo non-CKD subgroups. The incidence of adjudicated DKA at week 52 in inTandem 1 and 2 was 1%, 5%, and 3%, respectively, for the placebo, 200 mg, and 400 mg doses in the CKD subgroup, compared to 0%, 3%, and 4% in the non-CKD subgroup.

Results were generally similar in inTandem3 except systolic BP was significantly reduced with sotagliflozin versus placebo in CKD and non-CKD subgroups.

“There hasn’t been a new drug approved for patients living with type 1 diabetes and chronic kidney disease in decades,” said study co-author and kidney specialist David Cherney, MD, PhD, University Health Network, University of Toronto. “Previous studies have shown the SGLT inhibitors – including sotagliflozin – lower blood pressure and harmful urinary protein levels to a similar degree in people with type 1 diabetes compared to people with type 2 diabetes. Our current analysis adds important evidence showing that sotagliflozin has the potential to provide benefits for patients with type 1 diabetes and chronic kidney disease, particularly when appropriate steps are taken to reduce the risk of diabetic ketoacidosis.”

“People with T1D and CKD urgently need new treatment options. We believe the findings of this analysis support our position that, if approved by the FDA, sotagliflozin should be included in discussions between clinicians and their patients with T1D and CKD about how to best achieve glycemic control,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer.

As previously reported, the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date for ZynquistaTM (sotagliflozin) of December 20, 2024.

Click here to read the abstract of the JASN manuscript.

About Sotagliflozin
Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients.

About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has commercially launched one of these medicines, INPEFA® (sotagliflozin) in the United States, and has a pipeline of other promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements,” including statements relating to sotagliflozin and Lexicon’s financial position and long-term outlook on its business, growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com


FAQ

What were the HbA1c reduction results for sotagliflozin in the LXRX T1D and CKD trials?

The trials showed placebo-adjusted HbA1c reductions of -0.4% for 200mg and -0.3% to -0.4% for 400mg doses in both CKD and non-CKD patients.

When is the FDA PDUFA date for Lexicon's (LXRX) Zynquista?

The FDA has set a PDUFA target action date of December 20, 2024, for Zynquista (sotagliflozin).

What were the hypoglycemia rates for sotagliflozin in LXRX's CKD patient trials?

In CKD patients, severe hypoglycemia rates were 7% for 200mg and 4% for 400mg sotagliflozin, compared to 17% for placebo.

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

LXRX Rankings

LXRX Latest News

LXRX Stock Data

430.18M
361.49M
1.15%
79.32%
7.65%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
THE WOODLANDS